The Israel Leukemia Registry: Integration of an AML Clinical Database with Personalized Ex Vivo and In Vivo Validated Single-Cell Characteristics to Improve Prognosis             
Grant Amount: NIS 4.2 Million
About the Project
This project will advance the understanding of the molecular basis of Acute Myeloid Leukemia (AML), one of the most aggressive blood cancers. The project will establish a national registry of Israeli AML patients, including clinical data as well as genetic and molecular characteristics, and the drug responsiveness of patient-derived AML cells. The resulting unique integrated database will be available to attending physicians for the purpose of optimizing AML treatment in a personalized manner.
Research Team
Prof. Michael Danilenko
Ben-Gurion University, Clinical Biochemistry and Pharmacology-Health Sciences
Dr. Eitan Rubin
Ben-Gurion University, Shraga Segal Department of Microbiology, Immunology and Genetics
Dr. Michael Milyavsky
Tel Aviv University, Department of Pathology, Sackler School of Medicine
Prof. Mordechai Deutsch
Bar-Ilan University, Physics
More Projects Funded